Personalis (NASDAQ:PSNL) Stock Rating Upgraded by Zacks Research

Personalis (NASDAQ:PSNL) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday, Zacks reports.

A number of other brokerages have also weighed in on PSNL. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Friday, July 17th. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Needham & Company LLC lowered Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Morgan Stanley raised their price target on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Personalis currently has an average rating of “Hold” and a consensus price target of $14.54.

Personalis Price Performance

Shares of PSNL opened at $16.60 on Monday. The firm has a market cap of $1.74 billion, a P/E ratio of -15.23 and a beta of 2.31. Personalis has a 1 year low of $4.95 and a 1 year high of $18.89. The company has a 50 day simple moving average of $14.68 and a two-hundred day simple moving average of $10.41.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The company had revenue of $22.36 million during the quarter, compared to analysts’ expectations of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. On average, sell-side analysts anticipate that Personalis will post -1.07 earnings per share for the current year.

Insider Transactions at Personalis

In related news, CFO Aaron Tachibana sold 51,251 shares of Personalis stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $13.18, for a total value of $675,488.18. Following the completion of the transaction, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,620,618.94. This trade represents a 20.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Hall sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total value of $1,508,000.00. Following the sale, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,558,668.88. This trade represents a 29.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 256,233 shares of company stock valued at $3,568,236. 4.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Merck & Co. Inc. bought a new stake in shares of Personalis in the 2nd quarter worth about $188,202,236. T. Rowe Price Investment Management Inc. grew its stake in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after buying an additional 7,896,714 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Personalis in the second quarter worth approximately $94,905,000. Kennedy Capital Management LLC lifted its stake in shares of Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after acquiring an additional 1,281,695 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in Personalis during the 2nd quarter valued at $24,395,000. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.